Evidence map›Paper›PMID 32154453›Full record

ArticleKidney international reports2020

A Systematic Review and Meta-Analysis of Depression and Protein-Energy Wasting in Kidney Disease.

L Parker Gregg, Thomas Carmody, Dustin Le, Gerard Martins, Madhukar Trivedi, S Susan Hedayati

Abstract read
In one paragraph

Article in Kidney international reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Five Things to Know About Depression in Hemodialysis.Canadian journal of kidney health and disease · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Fatigue in CKD: Epidemiology, Pathophysiology, and Treatment.Clinical journal of the American Society of Nephrology : CJASN · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

L Parker GreggDivision of Nephrology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Thomas CarmodyDepartment of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Dustin LeDepartment of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Gerard MartinsDivision of Nephrology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Madhukar TrivediDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
S Susan HedayatiDivision of Nephrology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Funding

Randomized trial of sertraline treatment of depression in Chronic Kidney DiseaseR01DK085512 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HEDAYATI, SUSAN · 2011 to 2015
$1.8M
Randomized trial of sertraline treatment of depression in Chronic Kidney DiseaseI01CX000217 · VA · VA NORTH TEXAS HEALTH CARE SYSTEM · PI HEDAYATI, SUSAN · 2009 to 2012
–
CSRD VA I01 CX000217NIDDK NIH HHS R01 DK085512
6 · The paper itself

Abstract

introductionDepression comorbid with chronic disease may be mediated by inflammation. We sought to characterize relationships between inflammatory biomarkers and depressive symptoms in patients with chronic kidney disease and end-stage kidney disease.

methodsA systematic literature search was conducted by 2 authors up to March 19, 2019, for studies of patients with chronic kidney disease or end-stage kidney disease evaluating circulating inflammatory biomarkers associated with depression of chronic disease: albumin, C-reactive protein (CRP), high-sensitivity CRP, interleukin-6 (IL-6), tumor necrosis factor-α, and interleukin-1. Standardized mean differences in biomarkers between individuals with and without depression were computed and analyzed using mixed effects models. Correlations between biomarkers and the severity of depressive symptoms were computed.

resultsThirty-four studies (5652 participants) compared biomarkers between depressed and nondepressed individuals. Individuals with depression had lower albumin levels (standardized mean difference, -0.37; 95% confidence interval [CI], -0.61 to -0.13), higher CRP levels (standardized mean difference, 0.76; 95% CI, 0.16-1.37), and higher IL-6 levels (standardized mean difference, 0.42; 95% CI, 0.21-0.63). Studies were heterogeneous for albumin, CRP, high-sensitivity CRP, and tumor necrosis factor-α. Twenty-three studies (3047 participants) investigated correlations between biomarkers and depressive symptoms. The severity of depressive symptoms correlated with albumin (

conclusionLower albumin and higher IL-6 were associated with both the presence and severity of depression, CRP with the presence of depression, and high-sensitivity CRP with the severity of depressive symptoms. The effect of interventions to lower inflammation in patients with kidney disease and depression deserves investigation.

Indexed as

albuminchronic kidney diseaseC-reactive proteindepressionhemodialysisinflammation

Identifiers

PMID32154453
PMCPMC7056860

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.